Cost-effectiveness of rapid assessment of potential ischaemic heart disease with CT coronary angiography.

Praveen Thokala Steve GoodacreKatherine OateyRachel O'BrienDavid E NewbyAlasdair Gray

Published in: Heart (British Cardiac Society) (2023)

There are no demonstrable differences in within-trial costs and QALYs, and long-term cost-effectiveness modelling suggested higher long-term costs with CTCA and uncertain effect on long-term QALYs, making routine use of CTCA for suspected ACS unlikely to be a cost-effective use of NHS resources.

Keyphrases

acute coronary syndrome
computed tomography
clinical trial
study protocol
patient safety
phase iii
pulmonary embolism
pulmonary hypertension
clinical practice
randomized controlled trial
phase ii
dual energy
magnetic resonance
climate change
risk assessment
human health
clinical evaluation